DCBLD1 Overexpression Is Associated With a Poor Prognosis in Head and Neck Squamous Cell Carcinoma.
DCBLD1
biomarker
head and neck squamous cell carcinoma
immune infiltrates
prognosis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
05
2022
accepted:
07
06
2022
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
20
7
2022
Statut:
epublish
Résumé
DCBLD1 is highly expressed in several kinds of cancer and plays a potential prognostic factor. However, the prognostic value and immune infiltration in head and neck squamous cell carcinoma remain unclear and need further research. DCBLD1 expression and clinical information were obtained from the Cancer Genome Atlas (TCGA) database. The mRNA level in cell lines (SCC25 and CAL27) and gingival fibroblasts were detected using quantitative PCR. Cox regression analysis was used to evaluate the prognostic values of DCBLD1 and clinical data in HNSCC. A nomogram was also established to predict the impact of DCBLD1 on prognosis based on Cox multivariate results. The methylation level of DCBLD1 in HNSC and its prognosis were analyzed in UALACN and MethSurv. Finally, the potential biological functions of DCBLD1 were investigated using gene set enrichment analysis (GSEA) and single-sample GSEA (ssGSEA). The mRNA and protein expression levels of DCBLD1 were highly expressed in HNSCC tissue and cell lines. The Cox analyses demonstrate that highly expressed DCBLD1 is an independent prognosis marker ( In head and neck squamous cell carcinoma, DCBLD1 is overexpressed, associated with poor patient prognosis. The detailed underlying mechanism merits further research.
Sections du résumé
Background
DCBLD1 is highly expressed in several kinds of cancer and plays a potential prognostic factor. However, the prognostic value and immune infiltration in head and neck squamous cell carcinoma remain unclear and need further research.
Materials and Methods
DCBLD1 expression and clinical information were obtained from the Cancer Genome Atlas (TCGA) database. The mRNA level in cell lines (SCC25 and CAL27) and gingival fibroblasts were detected using quantitative PCR. Cox regression analysis was used to evaluate the prognostic values of DCBLD1 and clinical data in HNSCC. A nomogram was also established to predict the impact of DCBLD1 on prognosis based on Cox multivariate results. The methylation level of DCBLD1 in HNSC and its prognosis were analyzed in UALACN and MethSurv. Finally, the potential biological functions of DCBLD1 were investigated using gene set enrichment analysis (GSEA) and single-sample GSEA (ssGSEA).
Results
The mRNA and protein expression levels of DCBLD1 were highly expressed in HNSCC tissue and cell lines. The Cox analyses demonstrate that highly expressed DCBLD1 is an independent prognosis marker (
Conclusion
In head and neck squamous cell carcinoma, DCBLD1 is overexpressed, associated with poor patient prognosis. The detailed underlying mechanism merits further research.
Identifiants
pubmed: 35844572
doi: 10.3389/fimmu.2022.939344
pmc: PMC9283650
doi:
Substances chimiques
RNA, Messenger
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
939344Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 Fu, Yan, Ma, Luo, Shao, Gosau, Friedrich, Vollkommer, Feng and Smeets.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancers (Basel). 2021 Sep 02;13(17):
pubmed: 34503236
Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Aug;132(2):202-209
pubmed: 34034998
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Genome Biol. 2014;15(12):550
pubmed: 25516281
BMC Cancer. 2020 Oct 12;20(1):982
pubmed: 33046035
Sci Rep. 2021 Jun 17;11(1):12753
pubmed: 34140574
BMC Genomics. 2016 Jan 08;17:38
pubmed: 26747525
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Front Oncol. 2021 Mar 08;11:608842
pubmed: 33763352
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Mol Cancer Res. 2018 Jan;16(1):90-102
pubmed: 28928286
Cancer Lett. 2016 Jan 1;370(1):85-90
pubmed: 26477683
Adv Drug Deliv Rev. 2016 Feb 1;97:28-40
pubmed: 26519775
F1000Res. 2018 Mar 14;7:316
pubmed: 29560265
Front Genet. 2020 May 06;11:435
pubmed: 32435261
Cancer. 2016 Nov 15;122(21):3344-3353
pubmed: 27533448
Biochem J. 2017 Nov 21;474(23):3963-3984
pubmed: 29025973
Oncogene. 2020 May;39(20):4092-4102
pubmed: 32231272
J Immunother Cancer. 2019 Aug 22;7(1):224
pubmed: 31439034
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Semin Cancer Biol. 2022 Nov;86(Pt 3):542-565
pubmed: 35151845
Cancer Treat Res. 2006;130:103-24
pubmed: 16610705
J Mater Chem B. 2016 Apr 7;4(13):2280-2289
pubmed: 32263223
Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515
pubmed: 30395287
J Cancer. 2021 May 5;12(13):3887-3899
pubmed: 34093796
Oral Oncol. 2022 Feb;125:105717
pubmed: 35034851
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Oncol Lett. 2021 Nov;22(5):784
pubmed: 34594425
Biochim Biophys Acta Proteins Proteom. 2017 Sep;1865(9):1160-1166
pubmed: 28668639
BMC Med Res Methodol. 2014 Feb 19;14:26
pubmed: 24552686
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Angiogenesis. 2008;11(1):31-9
pubmed: 18283547
Biochem J. 2019 Mar 22;476(6):931-950
pubmed: 30902898
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
Nat Genet. 2012 Dec;44(12):1330-5
pubmed: 23143601
Curr Biol. 2020 Aug 17;30(16):R921-R925
pubmed: 32810447
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Adv Exp Med Biol. 2002;515:55-69
pubmed: 12613543
Front Oncol. 2020 Feb 05;10:68
pubmed: 32117725
Cancers (Basel). 2019 Dec 24;12(1):
pubmed: 31878157
Cancers (Basel). 2021 Feb 13;13(4):
pubmed: 33668519
Inflammation. 2022 Jun;45(3):1162-1173
pubmed: 35064377